Old Web
English
Sign In
Acemap
>
Paper
>
O17-2 Tafasitamab + lenalidomide versus lenalidomide monotherapy in transplant-ineligible patients with R/R DLBCL (RE-MIND)
O17-2 Tafasitamab + lenalidomide versus lenalidomide monotherapy in transplant-ineligible patients with R/R DLBCL (RE-MIND)
2021
Grzegorz S. Nowakowski
Thomas D. Rodgers
Dario Marino
Maurizio Frezzato
Anna Maria Barbui
Claudia Castellino
Erika Meli
Nathan Fowler
Bruce Feinberg
Sascha Tillmanns
Stephan Parche
Günter Fingerle-Rowson
Mark Winderlich
Sumeet Ambarkhane
Gilles Salles
Pier Luigi Zinzani
Keywords:
Oncology
Medicine
Internal medicine
transplant ineligible
Lenalidomide
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]